We’re putting the finishing touches on something special — ordering opens soon. Stay tuned.
← Back to Catalog

Cagrilintide

Cagrilintide vial frontCagrilintide vial back
Loading...

Summary

NN9709

Cagrilintide is a once-weekly injectable peptide that mimics amylin, a hormone that helps control appetite. Large clinical trials showed it helped people lose about 12% of their body weight over 68 weeks. The most common side effects were nausea and digestive issues, similar to other weight loss medications.

Current Research
  • Appetite regulation via amylin signaling
  • Body weight in obesity research
  • Metabolic outcomes in combination therapy
Identification
CAS
1415456-99-3
Formula
C203H321N57O64S2
M.W.
4409 g/mol

Key Research Statistics

Next-Generation Weight Management

~7 daysHalf-LifeOnce-weekly dosing — FDA submission December 2025
Weight Loss — REDEFINE 1 (68 Weeks)
Phase 3, n=3,417 — 22 countries
CagriSema20.4%
Semaglutide Alone14.9%
Cagrilintide Alone11.5%
Placebo3%
REDEFINE 1 Phase 3
Responder Thresholds (CagriSema)
Patients achieving target weight loss
≥5% Loss91.9%
≥20% Loss51.7%
≥25% Loss33.7%
REDEFINE 1
Metabolic Improvements (CagriSema)
Waist (−13.4 cm)13.4
SBP (−6.7 mmHg)6.7
HbA1c (−1.91%)1.91
REDEFINE 1

Need-to-Know

  • Room Temperature (Lyophilized): 4-8 weeks
  • Refrigerated (Reconstituted): Up to 30 days
  • Frozen (Lyophilized): 12-24 months
  • Reconstitution Solution: Bacteriostatic water, Sterile water
  • Appearance: White to off-white powder

Regulatory Status

Not FDA-approvedInvestigationalPhase 3

Phase 3 trials for obesity and type 2 diabetes. Showing promising results in clinical studies.

Sources: ClinicalTrials.gov

History

2010s
Developed as long-acting version of amylin, a hormone that reduces appetite.
2020s
Combined with another weight loss drug; showed 22.7% weight loss in trials.

3D Structure

39-amino-acid peptide · 4409 g/mol

Interactive model
Cagrilintide molecule previewExplore 3D Structure

Cagrilintide at the Cellular Level

Long-acting amylin analog

Mechanism
Cagrilintide cellular mechanism preview

Cagrilintide in the Body

Long-acting amylin analog

Metabolic
Cagrilintide in the Body

Research Library

Peer-reviewed studies

From Published Literature

"Both pramlintide and cagrilintide are safe, effective, and promising drugs that successfully reduce body weight in patients with T2DM and regulate glucose homeostasis."

Dr. Stjepan ErženPeer-reviewed Review
Verify on PubMed

Complete Your Protocol

Complementary compounds from other research areas